CC
SNTI icon

Centiva Capital’s Senti Biosciences Holdings SNTI Stock Holding History

Centiva Capital’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,382
Closed -$336K – 1577
2021
Q2 		$336K Buy
+3,382
New +$337K 0.01% 1005

Other funds holding SNTI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
DCP
D1 Capital Partners New York $34.8B AUM 11.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Centiva Capital's SNTI Position: Q3 2021 in Review

Centiva Capital sold out of Senti Biosciences Holdings (SNTI) in Q3 2021, closing a stake of 3,382 shares — an estimated $336K sold.

Centiva Capital first reported a position in SNTI in Q2 2021 and held it in 1 quarter. The position peaked at $336K in Q2 2021. 39 funds tracked by Wall St. Rank hold SNTI as of Q3 2021.

  • Centiva Capital reported no remaining Senti Biosciences Holdings position as of Q3 2021 after selling out during the quarter.
  • Centiva Capital sold 3,382 Senti Biosciences Holdings shares in Q3 2021, an estimated $336K.
  • Centiva Capital first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 1 quarter.
  • Centiva Capital's Senti Biosciences Holdings position peaked at $336K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.